Navidea Biopharmaceuticals Inc. (NAVB)

0.24
0.01 4.64
AMEX : Health Technology
Prev Close 0.23
Open 0.24
Day Low/High 0.23 / 0.24
52 Wk Low/High 0.21 / 0.68
Volume 57.05K
Avg Volume 306.70K
Exchange AMEX
Shares Outstanding 162.96M
Market Cap 38.57M
EPS -0.10
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Navidea Biopharmaceuticals Reports First Quarter 2018 Financial Results

Navidea Biopharmaceuticals Reports First Quarter 2018 Financial Results

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced its financial results for the first quarter of 2018.

Navidea Biopharmaceuticals Schedules First Quarter 2018 Earnings Conference Call And Business Update

Navidea Biopharmaceuticals Schedules First Quarter 2018 Earnings Conference Call And Business Update

Navidea Biopharmaceuticals (NYSE MKT: NAVB) ("Navidea" or "the Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced it will host a conference call on Wednesday, May 9, 2018 at...

Navidea Biopharmaceuticals Schedules Conference Call To Discuss Future Outlook And Outcomes Of Court Trial

Navidea Biopharmaceuticals Schedules Conference Call To Discuss Future Outlook And Outcomes Of Court Trial

Navidea Biopharmaceuticals (NYSE MKT: NAVB) ("Navidea" or "the Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced it will host a conference call...

Navidea Biopharmaceuticals To Present At 25th Annual Future Leaders In The Biotech Industry

Navidea Biopharmaceuticals To Present At 25th Annual Future Leaders In The Biotech Industry

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced it will present at...

Navidea Biopharmaceuticals Reports Fourth Quarter And Full Year 2017 Financial Results

Navidea Biopharmaceuticals Reports Fourth Quarter And Full Year 2017 Financial Results

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced its financial results...

Navidea Biopharmaceuticals Schedules Fourth Quarter And Full Year 2017 Earnings Conference Call And Business Update

Navidea Biopharmaceuticals Schedules Fourth Quarter And Full Year 2017 Earnings Conference Call And Business Update

Navidea Biopharmaceuticals (NYSE MKT: NAVB) ("Navidea" or "the Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced it will host a conference call...

Navidea To Host Moderated Q&A Webcast With Management

Navidea To Host Moderated Q&A Webcast With Management

Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, announced today that it will hold an online Question & Answer...

Navidea Biopharmaceuticals To Present At Biotech Showcase 2018

Navidea Biopharmaceuticals To Present At Biotech Showcase 2018

Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that it will be presenting at the Biotech Showcase in...

Navidea Biopharmaceuticals To Present At LD Micro 10th Annual Main Event

Navidea Biopharmaceuticals To Present At LD Micro 10th Annual Main Event

Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced it will present at the LD Micro 10 th Annual Main...

Navidea Biopharmaceuticals Reports Third Quarter 2017 Financial Results

Navidea Biopharmaceuticals Reports Third Quarter 2017 Financial Results

Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced its financial results for the...

Navidea To Present Late-Breaking Abstract At American College Of Rheumatology Annual Meeting

Navidea To Present Late-Breaking Abstract At American College Of Rheumatology Annual Meeting

Navidea Biopharmaceuticals (NYSE MKT: NAVB), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, announced today that it will present a poster during the late-breaking abstract...

Navidea Biopharmaceuticals Schedules Third Quarter 2017 Earnings Conference Call And Business Update

Navidea Biopharmaceuticals Schedules Third Quarter 2017 Earnings Conference Call And Business Update

Navidea Biopharmaceuticals (NYSE MKT: NAVB) ("Navidea" or "the Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced it will host a conference call...

Navidea Signs Letter Of Intent To Sublicense NAV4694 Worldwide Development Rights

Navidea Signs Letter Of Intent To Sublicense NAV4694 Worldwide Development Rights

Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced the execution of a non-binding letter of intent with...

Navidea Biopharmaceuticals To Present At The Rodman & Renshaw 19th Annual Global Investment Conference

Navidea Biopharmaceuticals To Present At The Rodman & Renshaw 19th Annual Global Investment Conference

Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) ("Navidea" or "the Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced it will present at the Rodman...

Navidea To Initiate Regular Webcast Series Featuring Moderated Q&A With Management

Navidea To Initiate Regular Webcast Series Featuring Moderated Q&A With Management

Navidea Biopharmaceuticals (NYSE MKT: NAVB) (Navidea or The Company), a company focused on the development of precision immunodiagnostic agents and through its subsidiary Macrophage Therapeutics, immunotherapeutics,...

Navidea Biopharmaceuticals Reports Second Quarter 2017 Financial Results

Navidea Biopharmaceuticals Reports Second Quarter 2017 Financial Results

Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) (Navidea or the Company), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced its financial results for the...

Navidea Enters Exclusive License And Distribution Agreement For India With Sayre Therapeutics

Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) ("Navidea"), a company focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics, today announced that it has entered into...

Navidea's Commercial Partner, Norgine B.V., Launches LYMPHOSEEK® In Europe

Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) ("Navidea"), a company focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics, today announced that its European...

Navidea Biopharmaceuticals To Present At The 7th Annual LD Micro Invitational Investor Conference

Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) ("Navidea" or "the Company"), a company focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics, today announced it will...

Navidea Biopharmaceuticals Reports First Quarter 2017 Financial Results

Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) ("Navidea" or "the Company"), a company focused on the development and commercialization of precision immunodiagnostic agents, today announced its financial results for the...

Navidea Biopharmaceuticals Invited To Present Data At Two Major Upcoming Conferences

Navidea Biopharmaceuticals, Inc. (NYSE MKT:NAVB) ("Navidea") ("the Company"), a company focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics, today announced that it...

Navidea Provides Corporate Update And Reports Full Year 2016 Results

Navidea Biopharmaceuticals, Inc. (NYSE MKT:NAVB) today reported business and financial highlights for the fourth quarter and year ended December 31, 2016.

Navidea Completes Sale Of North American Rights Of Lymphoseek® To Cardinal Health

Navidea Biopharmaceuticals (NYSE MKT: NAVB) announced today the completion of the sale to Cardinal Health (NYSE: CAH) of its Lymphoseek® product for lymphatic mapping, lymph node biopsy and the diagnosis of metastatic...

Navidea To Hold Conference Call To Provide Investor Update On Status Of Ongoing Corporate Events

Navidea Biopharmaceuticals, Inc. (NYSE MKT:NAVB) today announced that management will hold an audio webcast conference call on Tuesday, January 31, 2017 at 4:30 p.

Navidea To Present At Upcoming Investor Conference

Navidea To Present At Upcoming Investor Conference

Navidea Biopharmaceuticals, Inc. (NYSE MKT:NAVB) today announced that management will present at an upcoming investor conference.

Navidea Signs Asset Purchase Agreement With Cardinal Health

Navidea Signs Asset Purchase Agreement With Cardinal Health

Navidea Biopharmaceuticals (NYSE MKT: NAVB) today announced that it has entered into a definitive asset purchase agreement with Cardinal Health (NYSE: CAH).

Navidea Reports 2016 Third Quarter Financial Results

Navidea Reports 2016 Third Quarter Financial Results

Navidea Biopharmaceuticals (NYSE MKT:NAVB) reports financial results for the quarter ending September 30, 2016.

Navidea Biopharmaceuticals To Announce Third Quarter 2016 Financial Results On November 3, 2016

Navidea Biopharmaceuticals To Announce Third Quarter 2016 Financial Results On November 3, 2016

Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) today announced that the Company will report its financial results for the third quarter of 2016, on Thursday, November 3, 2016 prior to a conference call with the...

TheStreet Quant Rating: D- (Sell)